Rathbones Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Rathbones Group’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,500	Closed	-$217K	–	645
2025 Q2	$217K	Hold	16,500	–	–	﹤0.01%	544
2025 Q1	$237K	Sell	16,500 -150	-0.9%	-$2.45K	﹤0.01%	501
2024 Q4	$279K	Sell	16,650 -13,750	-45%	-$228K	﹤0.01%	479
2024 Q3	$486K	Sell	30,400 -900	-3%	-$11K	﹤0.01%	420
2024 Q2	$283K	Hold	31,300	–	–	﹤0.01%	498
2024 Q1	$354K	Hold	31,300	–	–	﹤0.01%	461
2023 Q4	$249K	Hold	31,300	–	–	﹤0.01%	501
2023 Q3	$203K	Buy	+31,300	New	+$214K	﹤0.01%	538

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Rathbones Group's CNTA Position: Q3 2025 in Review

Rathbones Group sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 16,500 shares — an estimated $217K sold.

Rathbones Group first reported a position in CNTA in Q3 2023 and held it in 8 quarters. The position peaked at $486K in Q3 2024. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

Rathbones Group reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Rathbones Group sold 16,500 Centessa Pharmaceuticals shares in Q3 2025, an estimated $217K.
Rathbones Group first reported a position in Centessa Pharmaceuticals in Q3 2023 and held it in 8 quarters.
Rathbones Group's Centessa Pharmaceuticals position peaked at $486K in Q3 2024.
125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Rathbones Group's 13F filing for Q3 2025, filed 13 Nov 2025.